Toripalimab

Programmed Death Receptor-1 Blocking Antibody — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Toripalimab is a drug in the Programmed Death Receptor-1 Blocking Antibody class catalogued in DrugCentral. It was first approved by the FDA in 2023. Its mechanism of action is classified as Programmed Death Receptor-1-directed Antibody Interactions. DrugCentral lists 1 molecular target, including PDCD1. Recorded indications include Metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC).

• Drug class: Programmed Death Receptor-1 Blocking Antibody.
• Mechanism of action: Programmed Death Receptor-1-directed Antibody Interactions.
• Molecular targets: PDCD1 (1 listed in DrugCentral).
• Indications: Metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC).
• ATC code: L01FF13 (PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC)

Mechanism & targets

• Mechanism of action (MoA): Programmed Death Receptor-1-directed Antibody Interactions
• Established pharmacologic class: Programmed Death Receptor-1 Blocking Antibody

Molecular targets (1)

Target	Gene	Action	Activity
Programmed cell death protein 1	PDCD1	other	Kd 9.52

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2023-10-27	FDA	—	COHERUS BIOSCIENCES INC	Yes

ATC classification

ATC code	Therapeutic hierarchy
L01FF13	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Myelosuppression	2988.9
White blood cell count decreased	322.9
Off label use	250.0
Hypothyroidism	180.7
Neutrophil count decreased	156.0
Hypoproteinaemia	141.0
Platelet count decreased	75.4
Hepatic function abnormal	74.0

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Toripalimab used for?

DrugCentral lists the following indications for Toripalimab: Metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC).

How does Toripalimab work?

Toripalimab is classified as Programmed Death Receptor-1-directed Antibody Interactions; its molecular targets in DrugCentral include PDCD1.

When was Toripalimab first approved?

Toripalimab was first approved by the FDA in 2023.

What drug class does Toripalimab belong to?

Toripalimab is in the Programmed Death Receptor-1 Blocking Antibody class.

Sources

• DrugCentral drug card 5757 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4297843 — compound record and bioactivity
• DrugBank DB15043 — drug record
• FDA UNII 8JXN261VVA — substance identity
• DailyMed: FDA labels for Toripalimab — current prescribing information (label search)
• UniProt Q15116 (PDCD1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.